 NEW YORK, May 1, 2021 PRNewswire -- Relmada Therapeutics, Inc. Nasdaq: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, today announced that clinical data related to REL-1017, the companys lead product candidate, will be presented in two posters at the American Psychiatric Association APA Annual Meeting 2021, which is being held virtually between May 1 and May 3, 2021. Details of the poster presentations are below: DateTime: May 1, 2021, from 1:00 1:30 PM ET Poster Number: 5181 Title: Rapid and Sustained Antidepressant Effects of REL-1017 esmethadone as an Adjunctive Treatment for Major Depressive Disorder: A Phase 2 Trial DateTime: May 1, 2021, from 1:00 1:30 PM ET Poster Number: 5198 Title: Effect of Percentage of Life-Years from the Start of Major Depressive Disorder on the Therapeutic Response of REL-1017 The on-demand posters are available for viewing online for the duration of the meeting by registered conference attendees. 